Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × bazlitoran × Clear all

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

pembrolizumab 60 Cyclophosphamide 53 Carboplatin 52 Paclitaxel 45 Nivolumab 42 Cisplatin 39 Dexamethasone 37 Gemcitabine 36 Radiotherapy 32 Capecitabine 29 Docetaxel 26 Rituximab 25 Bevacizumab 25 fludarabine 24 venetoclax 21 avelumab 21 atezolizumab 21 Cytarabine 21 Temozolomide 20 Fluorouracil 20 Trastuzumab 19 Oxaliplatin 19 Lenalidomide 19 Cetuximab 19 Bortezomib 19 Azacitidine 19 130-nm albumin-bound paclitaxel 19 fludarabine phosphate 18 Pemetrexed 18 Filgrastim 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02092909 2019-09-10

8400-401

Idera Pharmaceuticals, Inc.

Phase 1/2 Terminated

31 enrolled 18 charts

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡